Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 34) Show all publications
Lu, S. S., Rutegård, M., Ahmed, M., Häggström, C., Gylfe, Å., Harlid, S. & van Guelpen, B. (2023). Prediagnostic prescription antibiotics use and survival in patients with colorectal cancer: a swedish national register-based study. Cancer Epidemiology, Biomarkers and Prevention, 32(10), 1391-1401
Open this publication in new window or tab >>Prediagnostic prescription antibiotics use and survival in patients with colorectal cancer: a swedish national register-based study
Show others...
2023 (English)In: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 32, no 10, p. 1391-1401Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Antibiotics use is associated with higher colorectal cancer risk, but little is known regarding any potential effects on survival.

METHODS: We conducted a nationwide cohort study, using complete-population data from Swedish national registers between 2005 and 2020, to investigate prediagnostic prescription antibiotics use in relation to survival in colorectal cancer patients.

RESULTS: We identified 36,061 stage I-III and 11,242 stage IV colorectal cancer cases diagnosed between 2010 and 2019. For stage I-III, any antibiotics use (binary yes/no variable) was not associated with overall or cancer-specific survival. Compared with no use, moderate antibiotics use (total 11-60 days) was associated with slightly better cancer-specific survival [adjusted HR (aHR) = 0.93; 95% confidence interval (CI), 0.86-0.99)], whereas very high use (>180 days) was associated with worse survival [overall survival (OS) aHR = 1.42; 95% CI, 1.26-1.60, cancer-specific survival aHR = 1.31; 95% CI, 1.10-1.55]. In analyses by different antibiotic types, although not statistically significant, worse survival outcomes were generally observed across several antibiotics, particularly macrolides and/or lincosamides. In stage IV colorectal cancer, inverse relationships between antibiotics use and survival were noted.

CONCLUSIONS: Overall, our findings do not support any substantial detrimental effects of prediagnostic prescription antibiotics use on cancer-specific survival after colorectal cancer diagnosis, with the possible exception of very high use in stage I-III colorectal cancer. Further investigation is warranted to confirm and understand these results.

IMPACT: Although the study findings require confirmation, physicians probably do not need to factor in prediagnostic prescription antibiotics use in prognosticating patients with colorectal cancer.

Place, publisher, year, edition, pages
American Association For Cancer Research (AACR), 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-215390 (URN)10.1158/1055-9965.EPI-23-0340 (DOI)37490284 (PubMedID)2-s2.0-85173563887 (Scopus ID)
Funder
Cancerforskningsfonden i Norrland, LP17–2154Cancerforskningsfonden i Norrland, LP21-2275Region Västerbotten, RV-932777
Available from: 2023-10-27 Created: 2023-10-27 Last updated: 2024-02-20Bibliographically approved
Lu, S. S., Mohammed, Z., Häggström, C., Myte, R., Lindquist, E., Gylfe, Å., . . . Harlid, S. (2022). Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study. Journal of the National Cancer Institute, 114(1), 38-46
Open this publication in new window or tab >>Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study
Show others...
2022 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 114, no 1, p. 38-46Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Antibiotics use may increase colorectal cancer (CRC) risk by altering the gut microbiota, with suggestive evidence reported. Our study aims to investigate antibiotics use in relation to subsequent CRC risk.

METHODS: This is a nationwide, population-based study with a matched case-control design (first primary CRC cases and 5 matched, cancer-free controls). Complete-population data, extracted from Swedish national registers for the period 2005-2016, were used to calculate odds ratios and 95% confidence intervals.

RESULTS: We included 40 545 CRC cases and 202 720 controls. Using the full dataset, we found a positive association between more frequent antibiotics use and CRC, excluding antibiotics prescribed within 2 years of diagnosis attenuated results toward the null. In site-specific analyses, excluding the 2-year washout, the positive association was confined to the proximal colon (adjusted odds ratio for very high use vs no use = 1.17, 95% confidence interval = 1.05 to 1.31). For rectal cancer, an inverse association, which appears to be driven by women, was observed. Quinolones and sulfonamides and/or trimethoprims were positively associated with proximal colon cancer, whereas a more general inverse association, across antibiotics classes, was observed for rectal cancer. We found no association between methenamine hippurate, a urinary tract antiseptic not affecting the gut microbiota, and CRC risk.

CONCLUSIONS: This register-based study covering the entire population of Sweden found a robust association between antibiotics use and higher risk of proximal colon cancer and an inverse association with rectal cancer in women. This study strengthens the evidence from previous investigations and adds important insight into site-specific colorectal carcinogenesis.

Place, publisher, year, edition, pages
Oxford University Press, 2022
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Research subject
Epidemiology
Identifiers
urn:nbn:se:umu:diva-188711 (URN)10.1093/jnci/djab125 (DOI)000748167200010 ()34467395 (PubMedID)2-s2.0-85123649937 (Scopus ID)
Funder
Region Västerbotten, RV 932777
Available from: 2021-10-19 Created: 2021-10-19 Last updated: 2024-02-20Bibliographically approved
Ivarsson, L., de Arriba Sánchez de la Campa, M., Elfving, K., Yin, H., Gullsby, K., Stark, L., . . . Herrmann, B. (2022). Changes in testing and incidence of Chlamydia trachomatis and Neisseria gonorrhoeae: the possible impact of the COVID-19 pandemic in the three Scandinavian countries. Infectious Diseases, 54(9), 623-631
Open this publication in new window or tab >>Changes in testing and incidence of Chlamydia trachomatis and Neisseria gonorrhoeae: the possible impact of the COVID-19 pandemic in the three Scandinavian countries
Show others...
2022 (English)In: Infectious Diseases, ISSN 2374-4235, E-ISSN 2374-4243, Vol. 54, no 9, p. 623-631Article in journal (Refereed) Published
Abstract [en]

Background: This study aimed to investigate what impact the COVID-19 pandemic and its associated restrictions had on Chlamydia trachomatis and Neisseria gonorrhoeae infections in Sweden, Denmark and Norway, countries with very different governmental strategies for handling this pandemic.

Methods: Retrospective analysis of data collected via requests to Swedish regions and to health authorities in Denmark and Norway. The data were collected for the years 2018–2020 and the data from Sweden were more detailed.

Results: When the pandemic restrictions were installed in 2020, the number of reported chlamydia cases decreased. The decline was most pronounced in Norway 10.8% (2019: n = 28,446; 2020: n = 25,444) while it was only 3.1% in Denmark (2019: n = 35,688; 2020: n = 34,689) and 4.3% in Sweden (2019: n = 34,726; 2020: n = 33,339). Nucleic acid amplifications tests for chlamydia decreased in Sweden (10%) and Norway (18%) in 2020 compared to 2019, while in Denmark a 21% decrease was noted in April 2020 but thereafter increased to a higher level than 2019. The number of reported gonorrhoea cases decreased in Sweden (17%) and in Norway (39%) in 2020 compared to 2019, while a 21% increase was noted in Denmark.

Conclusions: Pandemic restrictions had an impact on the number of reported chlamydia infections in all three countries, but only temporarily and did not seem to be correlated to the restriction levels. The number of reported gonorrhoea infections in Sweden and Norway significantly decreased but not in Denmark. Pandemic restrictions appear to have had a limited effect on the spread of chlamydia and gonorrhoea.

Place, publisher, year, edition, pages
Taylor & Francis, 2022
Keywords
chlamydia, Chlamydia trachomatis, COVID-19, gonorrhoea, pandemic, sexually transmitted infections (STI)
National Category
Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-196111 (URN)10.1080/23744235.2022.2071461 (DOI)000792672900001 ()35527677 (PubMedID)2-s2.0-85130208207 (Scopus ID)
Available from: 2022-06-17 Created: 2022-06-17 Last updated: 2023-03-24Bibliographically approved
Vu, T. H., Adhel, E., Vielfort, K., Duong, N.-T. H., Anquetin, G., Jeannot, K., . . . Serradji, N. (2022). Modified Fluoroquinolones as Antimicrobial Compounds Targeting Chlamydia trachomatis. International Journal of Molecular Sciences, 23(12), Article ID 6741.
Open this publication in new window or tab >>Modified Fluoroquinolones as Antimicrobial Compounds Targeting Chlamydia trachomatis
Show others...
2022 (English)In: International Journal of Molecular Sciences, ISSN 1661-6596, E-ISSN 1422-0067, Vol. 23, no 12, article id 6741Article in journal (Refereed) Published
Abstract [en]

Chlamydia trachomatis causes the most common sexually transmitted bacterial infection and trachoma, an eye infection. Untreated infections can lead to sequelae, such as infertility and ectopic pregnancy in women and blindness. We previously enhanced the antichlamydial activity of the fluoroquinolone ciprofloxacin by grafting a metal chelating moiety onto it. In the present study, we pursued this pharmacomodulation and obtained nanomolar active molecules (EC50) against this pathogen. This gain in activity prompted us to evaluate the antibacterial activity of this family of molecules against other pathogenic bacteria, such as Neisseria gonorrhoeae and bacteria from the ESKAPE group. The results show that the novel molecules have selectively improved activity against C. trachomatis and demonstrate how the antichlamydial effect of fluoroquinolones can be enhanced.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
8-hydroxyquinoline, antibacterial, bactericidal, inhibitors, iron
National Category
Microbiology in the medical area
Identifiers
urn:nbn:se:umu:diva-203178 (URN)10.3390/ijms23126741 (DOI)000818267400001 ()35743189 (PubMedID)2-s2.0-85132015511 (Scopus ID)
Available from: 2023-01-16 Created: 2023-01-16 Last updated: 2023-01-16Bibliographically approved
Núñez-Otero, C., Bahnan, W., Vielfort, K., Silver, J., Singh, P., Elbir, H., . . . Gylfe, Å. (2021). A 2-pyridone amide inhibitor of transcriptional activity in Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy, 65(5), Article ID e01826-20.
Open this publication in new window or tab >>A 2-pyridone amide inhibitor of transcriptional activity in Chlamydia trachomatis
Show others...
2021 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 65, no 5, article id e01826-20Article in journal (Refereed) Published
Abstract [en]

Chlamydia trachomatis is a strict intracellular bacterium that causes sexually transmitted infections and eye infections that can lead to lifelong sequelae. Treatment options are limited to broad-spectrum antibiotics that disturb the commensal flora and contribute to selection of antibiotic-resistant bacteria. Hence, development of novel drugs that specifically target C. trachomatis would be beneficial. 2-Pyridone amides are potent and specific inhibitors of Chlamydia infectivity. The first-generation compound KSK120 inhibits the developmental cycle of Chlamydia, resulting in reduced infectivity of progeny bacteria. Here, we show that the improved, highly potent second-generation 2-pyridone amide KSK213 allowed normal growth and development of C. trachomatis, and the effect was only observable upon reinfection of new cells. Progeny elementary bodies (EBs) produced in the presence of KSK213 were unable to activate transcription of essential genes in early development and did not differentiate into the replicative form, the reticulate body (RB). The effect was specific to C. trachomatis since KSK213 was inactive in the closely related animal pathogen Chlamydia muridarum and in Chlamydia caviae. The molecular target of KSK213 may thus be different in C. trachomatis or nonessential in C. muridarum and C. caviae. Resistance to KSK213 was mediated by a combination of amino acid substitutions in both DEAD/DEAH RNA helicase and RNase III, which may indicate inhibition of the transcriptional machinery as the mode of action. 2-Pyridone amides provide a novel antibacterial strategy and starting points for development of highly specific drugs for C. trachomatis infections.

Place, publisher, year, edition, pages
American Society for Microbiology, 2021
Keywords
Chlamydia trachomatis, antibacterial agents, intracellular bacteria, mode of action, virulence inhibitors
National Category
Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-174665 (URN)10.1128/AAC.01826-20 (DOI)000641612600035 ()2-s2.0-85105036198 (Scopus ID)
Note

Originally included in thesis in manuscript form.

Available from: 2020-08-31 Created: 2020-08-31 Last updated: 2023-09-05Bibliographically approved
Agerhäll, M., Henrikson, M., Johansson Söderberg, J., Sellin, M., Tano, K., Gylfe, Å. & Berggren, D. (2021). High prevalence of pharyngeal bacterial pathogens among healthy adolescents and young adults. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), 129(12), 711-716
Open this publication in new window or tab >>High prevalence of pharyngeal bacterial pathogens among healthy adolescents and young adults
Show others...
2021 (English)In: Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), ISSN 0903-4641, E-ISSN 1600-0463, Vol. 129, no 12, p. 711-716Article in journal (Refereed) Published
Abstract [en]

The pharyngeal mucosa can be colonized with bacteria that have potential to cause pharyngotonsillitis. By the use of culturing techniques and PCR, we aimed to assess the prevalence of bacterial pharyngeal pathogens among healthy adolescents and young adults. We performed a cross-sectional study in a community-based cohort of 217 healthy individuals between 16 and 25 years of age. Samples were analyzed for Group A streptococci (GAS), Group C/G streptococci (SDSE), Fusobacterium necrophorum, and Arcanobacterium haemolyticum. Compared to culturing, the PCR method resulted in more frequent detection, albeit in most cases with low levels of DNA, of GAS (20/217 vs. 5/217; p < 0.01) and F. necrophorum (20/217 vs. 8/217; p < 0.01). Culturing and PCR yielded similar rates of SDSE detection (14/217 vs. 12/217; p = 0.73). Arcanobacterium haemolyticum was rarely detected (3/217), and only by PCR. Overall, in 25.3% (55/217) of these healthy adolescents and young adults at least one of these pathogens was detected, a rate that is higher than previously described. Further studies are needed before clinical adoption of PCR-based detection methods for pharyngeal bacterial pathogens, as our findings suggest a high incidence of asymptomatic carriage among adolescents and young adults without throat infections.

Place, publisher, year, edition, pages
John Wiley & Sons, 2021
Keywords
Adolescence, carriage, Fusobacterium necrophorum, pharyngeal bacteria, Streptococcus dysgalactiae subspecies equisimilis, Streptococcus pyogenes, young adulthood
National Category
Infectious Medicine Microbiology in the medical area
Research subject
Microbiology
Identifiers
urn:nbn:se:umu:diva-189129 (URN)10.1111/apm.13179 (DOI)000711821300001 ()34580908 (PubMedID)2-s2.0-85117912479 (Scopus ID)
Available from: 2021-11-09 Created: 2021-11-09 Last updated: 2023-04-17Bibliographically approved
Risum, M., Helweg-Larsen, J., Petersen, S. L., Kampmann, P., Overgaard, U. M., El Fassi, D., . . . Arendrup, M. C. (2020). Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis. JOURNAL OF FUNGI, 6(4), Article ID 268.
Open this publication in new window or tab >>Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis
Show others...
2020 (English)In: JOURNAL OF FUNGI, ISSN 2309-608X, Vol. 6, no 4, article id 268Article in journal (Refereed) Published
Abstract [en]

Mucormycosis is a life threatening infection in patients with haematological disease. We introduced a Mucorales-PCR and an aggressive, multidisciplinary management approach for mucormycosis during 2016-2017 and evaluated patient outcomes in 13 patients diagnosed and treated in 2012-2019. Management principle: repeated surgical debridement until biopsies from the resection margins were clean as defined by negative Blankophor microscopy, Mucorales-PCR (both reported within 24 h), and cultures. Cultured isolates underwent EUCAST E.Def 9.3.1 susceptibility testing. Antifungal therapy (AFT) (mono/combination) combined with topical AFT (when possible) was given according to the minimal inhibitory concentration (MIC), severity of the infection, and for azoles, specifically, it was guided by therapeutic drug monitoring. The outcome was evaluated by case record review. All patients underwent surgery guided by diagnostic biopsies from tissue and resection margins (195 samples in total). Comparing 2012-2015 and 2016-2019, the median number of patients of surgical debridements was 3 and 2.5 and of diagnostic samples: microscopy/culture/PCR was 3/3/6 and 10.5/10/10.5, respectively. The sensitivity of microscopy (76%) and Mucorales-PCR (70%) were similar and microscopy was superior to that of culture (53%; p = 0.039). Initial systemic AFT was liposomal amphotericin B (n = 12) or posaconazole (n = 1) given as monotherapy (n = 4) or in combination with isavuconazole/posaconazole (n = 3/6) and terbinafine (n = 3). Nine patients received topical amphotericin B. All received isavuconazole or posaconazole consolidation therapy (n = 13). Mucormycosis related six month mortality was 3/5 in 2012-2015 and 0/7 patients in 2016-2019 (one patient was lost for follow-up). Implementation of combination therapy (systemic+topical AFT/combination systemic AFT) and aggressive surgical debridement guided by optimised diagnostic tests may improve the outcome of mucormycosis in haematologic patients.

Place, publisher, year, edition, pages
MDPI, 2020
Keywords
Mucorales, mucormycosis, haematology, neutropenia and mortality
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:umu:diva-178721 (URN)10.3390/jof6040268 (DOI)000601670600001 ()33171634 (PubMedID)2-s2.0-85096094760 (Scopus ID)
Available from: 2021-01-14 Created: 2021-01-14 Last updated: 2023-03-23Bibliographically approved
Kulén, M., Núñez-Otero, C., Cairns, A. G., Silver, J., Lindgren, A. E. G., Andersson, E. K., . . . Almqvist, F. (2019). Methyl sulfonamide substituents improve the pharmacokinetic properties of bicyclic 2-pyridone based Chlamydia trachomatis inhibitors. MedChemComm, 10(11), 1966-1987
Open this publication in new window or tab >>Methyl sulfonamide substituents improve the pharmacokinetic properties of bicyclic 2-pyridone based Chlamydia trachomatis inhibitors
Show others...
2019 (English)In: MedChemComm, ISSN 2040-2503, E-ISSN 2040-2511, Vol. 10, no 11, p. 1966-1987Article in journal (Refereed) Published
Abstract [en]

Chlamydia trachomatis infections are a global health problem and new approaches to treat C. trachomatis with drugs of high specificity would be valuable. A library of substituted ring fused 2-pyridones has been synthesized and evaluated for their ability to attenuate C. trachomatis infectivity. In vivo pharmacokinetic studies were performed, with the best candidates demonstrating that a C8-methylsulfonamide substituent improved pharmacokinetic properties important for oral administration. C8-Methyl sulfonamide analogue 30 inhibited C. trachomatis infectivity in low micromolar concentrations. Further pharmacokinetic evaluation at an oral dose of 10 mg kg(-1) showed an apparent bioavailability of 41%, compared to C8-cyclopropyl and -methoxy analogues which had negligible oral uptake. In vitro ADME (absorption, distribution, metabolism and excretion) testing of solubility and Caco-2 cell permeability revealed that both solubility and permeability is greatly improved with the C8-methyl sulfonamide 30, effectively moving it from BCS (Biopharmaceutical Classification System) class IV to II.

Place, publisher, year, edition, pages
Royal Society of Chemistry, 2019
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:umu:diva-166479 (URN)10.1039/c9md00405j (DOI)000498725400013 ()2-s2.0-85075072755 (Scopus ID)
Funder
Swedish Cancer SocietyKnut and Alice Wallenberg FoundationGöran Gustafsson Foundation for Research in Natural Sciences and MedicineThe Kempe FoundationsSwedish Foundation for Strategic Research
Available from: 2020-01-02 Created: 2020-01-02 Last updated: 2023-08-25Bibliographically approved
Müller, D. C., Kauppi, A., Edin, A., Gylfe, Å., Sjöstedt, A. B. & Johansson, A. (2019). Phospholipid Levels in Blood during Community-Acquired Pneumonia. PLOS ONE, 14(5), Article ID e0216379.
Open this publication in new window or tab >>Phospholipid Levels in Blood during Community-Acquired Pneumonia
Show others...
2019 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 14, no 5, article id e0216379Article in journal (Refereed) Published
Abstract [en]

Phospholipids, major constituents of bilayer cell membranes, are present in large amounts in pulmonary surfactant and play key roles in cell signaling. Here, we aim at finding clinically useful disease markers in community-acquired pneumonia (CAP) using comprehensive phospholipid profiling in blood and modeling of changes between sampling time points. Serum samples from 33 patients hospitalized with CAP were collected at admission, three hours after the start of intravenous antibiotics, Day 1 (at 12–24 h), Day 2 (at 36–48 h), and several weeks after recovery. A profile of 75 phospholipid species including quantification of the bioactive lysophosphatidylcholines (LPCs) was determined using liquid chromatography coupled to time-of-flight mass spectrometry. To control for possible enzymatic degradation of LPCs, serum autotaxin levels were examined. Twenty-two of the 33 patients with a clinical diagnosis of CAP received a laboratory-verified CAP diagnosis by microbial culture or microbial DNA detection by qPCR. All major phospholipid species, especially the LPCs, were pronouncedly decreased in the acute stage of illness. Total and individual LPC concentrations increased shortly after the initiation of antibiotic treatment, concentrations were at their lowest 3h after the initiation, and increased after Day 1. The total LPC concentration increased by a change ratio of 1.6–1.7 between acute illness and Day 2, and by a ratio of 3.7 between acute illness and full disease resolution. Autotaxin levels were low in acute illness and showed little changes over time, contradicting a hypothesis of enzymatic degradation causing the low levels of LPCs. In this sample of patients with CAP, the results demonstrate that LPC concentration changes in serum of patients with CAP closely mirrored the early transition from acute illness to recovery after the initiation of antibiotics. LPCs should be further explored as potential disease stage biomarkers in CAP and for their potential physiological role during recovery.

Place, publisher, year, edition, pages
Public Library of Science, 2019
Keywords
Community-acquired pneumonia, phospholipids, infection, diagnosis, metabolomics
National Category
Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-147058 (URN)10.1371/journal.pone.0216379 (DOI)000467148400025 ()31063483 (PubMedID)2-s2.0-85065767332 (Scopus ID)
Note

Originally included in thesis in manuscript form 

Available from: 2018-04-25 Created: 2018-04-25 Last updated: 2023-03-23Bibliographically approved
Saleeb, M., Mojica, S., Eriksson, A. U., Andersson, C. D., Gylfe, Å. & Elofsson, M. (2018). Natural product inspired library synthesis – Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. European Journal of Medicinal Chemistry, 143, 1077-1089
Open this publication in new window or tab >>Natural product inspired library synthesis – Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis
Show others...
2018 (English)In: European Journal of Medicinal Chemistry, ISSN 0223-5234, E-ISSN 1768-3254, Vol. 143, p. 1077-1089Article in journal (Refereed) Published
Abstract [en]

A natural product inspired library was synthesized based on 2,3-diarylbenzofuran and 2,3-diaryl-2,3-dihydrobenzofuran scaffolds. The library of forty-eight compounds was prepared by utilizing Pd-catalyzed one-pot multicomponent reactions and ruthenium-catalyzed intramolecular carbenoid C-H insertions. The compounds were evaluated for antibacterial activity in a panel of test systems including phenotypic, biochemical and image-based screening assays. We identified several potent inhibitors that block intracellular replication of pathogenic Chlamydia trachomatis with IC50 ≤ 3 μM. These new C. trachomatis inhibitors can serve as starting points for the development of specific treatments that reduces the global burden of C. trachomatis infections.

Place, publisher, year, edition, pages
Elsevier, 2018
Keywords
2, 3-diaryl-2, 3-dihydrobenzofuran, 2, 3-diaryl-benzofuran, Antibacterial, Benzofuran, Chlamydia
National Category
Organic Chemistry Biological Sciences
Identifiers
urn:nbn:se:umu:diva-143062 (URN)10.1016/j.ejmech.2017.11.099 (DOI)000428216700089 ()29232584 (PubMedID)2-s2.0-85037621393 (Scopus ID)
Funder
Swedish Foundation for Strategic Research , SB12-0022Swedish Research Council, 621-2014-4670
Available from: 2017-12-18 Created: 2017-12-18 Last updated: 2023-03-24Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-8632-7087

Search in DiVA

Show all publications